Greg Collier
Chairman and Independent Director
Phosphagenics
Australia
Biography
Dr Collier is currently the CEO of ASX listed company Invion Ltd, and has more than 20 years’ experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has executed multiple commercial transactions and has successfully taken a drug from discovery through to regulatory approval. Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of $10M to a company that completed clinical trials and submitted regulatory dossiers to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. During Dr Collier’s distinguished academic career, before entering the commercial world, he published over 150 peer reviewed articles, as well as having senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University and also held positions at the University of Melbourne, Monash University and the University of Toronto. In 2010 Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.
Research Interest
Pharmaceutical Research
